Stockreport

Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF Beam Therapeutics recently reported additional safety and efficacy data from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease, [Read more]